405-66-3

Basic information

• Product Name: (4-FLUORO-BENZYL)-METHYL-AMINE
• Synonyms: CHEMBRDG-BB 4004372;(4-FLUORO-BENZYL)-METHYL-AMINE;4-FLUORO-N-METHYL BENZYLAMINE;AKOS BC-2746;TIMTEC-BB SBB005902;N-(4-FLUOROBENZYL)-N-METHYLAMINE;N-Methyl-4-fluorobenzylamine;4-Fluoro-N-Methyl Benzyla E
• CAS NO: 405-66-3
• Molecular Formula: C₈H₁₀FN
• Molecular Weight: 139.17
• Product Categories: Amines and Anilines;Polyamines;API intermediates;Amines;C8;Nitrogen Compounds
• Mol File: 405-66-3.mol
• Article Data: 21

Chemical Properties

• Boiling Point: 180-181 °C(lit.)
• Flash Point: 71 °C
• Appearance: /
• Density: 1.056 g/mL at 25 °C(lit.)
• Vapor Pressure: 1.12mmHg at 25°C
• Refractive Index: n20/D 1.4990(lit.)
• PKA: 9.71±0.10(Predicted)
• Sensitive: Air Sensitive
• CAS DataBase Reference: (4-FLUORO-BENZYL)-METHYL-AMINE(CAS DataBase Reference)
• NIST Chemistry Reference: (4-FLUORO-BENZYL)-METHYL-AMINE(405-66-3)
• EPA Substance Registry System: (4-FLUORO-BENZYL)-METHYL-AMINE(405-66-3)

Safety Data

• Hazard Codes: Xi
• Statements: 37/38-41-43
• Safety Statements: 26-36/37/39
• RIDADR: UN 2735 8/PG III
• WGK Germany: 3
• HazardClass: 8
• PackingGroup: III
• Hazardous Substances Data: 405-66-3(Hazardous Substances Data)

Usage

Uses

4-Fluoro-n-methylbenzylamine

InChI:InChI=1/C8H10FN/c1-10-6-7-2-4-8(9)5-3-7/h2-5,10H,6H2,1H3/p+1

Upstream product

• 84174-25-4 p-fluorobenzylamine formamide 
• 74-89-5 methylamine 
• 352-11-4 1-chloromethyl-4-fluorobenzene 
• 593-51-1 methylamine hydrochloride 
• 459-57-4 4-fluorobenzaldehyde 
• 140-75-0 para-fluorobenzylamine 
• 104156-56-1 1-(4-fluorophenyl)-N-methylmethanimine 
• 67-56-1 methanol 
• 159979-96-1 4-fluorobenzyl azide 
• 459-46-1 4-Fluorobenzyl bromide 
• 124-38-9 carbon dioxide 
• 333-27-7 methyl trifluoromethanesulfonate 
• 153903-23-2 (4-fluorobenzyl)carbamic acid tert-butyl ester 
• 167300-01-8 tert-butyl N-(4-fluorobenzyl)-N-methylcarbamate 

Downstream Products

• 368-06-9 (2-fluoro-benzyl)-(4-fluoro-benzyl)-methyl-amine 
• 76551-40-1 N⁶-(4-Fluoro-benzyl)-N⁶-methyl-pteridine-2,4,6-triamine 
• 871936-97-9 3-benzyloxy-2-[4-fluorobenzyl(methyl)aminocarbonyl]-5-methyl-4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine 
• 933759-96-7 C₁₁H₁₇FN₂ 
• 957113-04-1 C₃₄H₄₃F₂N₃O₆ 
• 1082604-47-4 C₂₁H₁₆FN₅ 
• 1174903-51-5 3-[[(4-fluorobenzyl)-methyl-amino]methyl]-5-(pyridin-4-yl)-1,3,4-oxadiazol-2(3H)-one 
• 1194045-77-6 C₁₈H₂₅FN₂O₃ 
• 1263808-10-1 2-{3-[(4-fluorobenzyl)methylamino]propyl}-10,10a-dihydro-5H-imidazo[1,5-b]isoquinoline-1,3-dione 
• 854023-07-7 N-(4-fluorobenzyl)-N,4-dimethylbenzenesulfonamide 
• 1417526-53-4 N-(4-fluorobenzyl)-N-methyl-1-(1-((4'-(trifluoromethyl)biphenyl-4-yl)methyl)-1H-imidazol-5-yl)methanamine 

Relevant articles and documents

Selective synthesis of mono- and di-methylated amines using methanol and sodium azide as C1 and N1 sources

A Ru(ii) complex mediated synthesis of various N,N-dimethyl and N-monomethyl amines from organic azides using methanol as a methylating agent is reported. This methodology was successfully applied for a one-pot reaction of bromide derivatives and sodium azide in methanol. Notably, by controlling the reaction time several N-monomethylated and N,N-dimethylated amines were synthesized selectively. The practical applicability of this tandem process was revealed by preparative scale reactions with different organic azides and synthesis of an anti-vertigo drug betahistine. Several kinetic experiments and DFT studies were carried out to understand the mechanism of this transformation.

Photocatalyzed cascade Meerwein addition/cyclization of: N -benzylacrylamides toward azaspirocycles

A visible-light-induced cascade Meerwein addition/cyclization of alkenes involving C-F bond cleavage was developed. This method offers a rapid access to azaspirocyclic cyclohexadienones from N-benzylacrylamides via C-F bond cleavage applying H2O as an external oxygen source, allowing for the incorporation of various aromatic moieties originating from aryldiazonium salts.

NECROSIS INHIBITORS

The invention provides amides that inhibit cellular necrosis and/or human receptor interacting protein 1 kinase (RIP1), including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.